[{"Assets_0_Q2_USD":204136000.0,"CommonStockSharesOutstanding_0_Q2_shares":11957491.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-6519000.0,"NetIncomeLoss_1_Q2_USD":-14603000.0,"NetIncomeLoss_2_Q2_USD":-16222000.0,"StockholdersEquity_0_Q2_USD":149447000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":730000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":11932000.0,"Ticker":"ALBO","CIK":"1322505","name":"ALBIREO PHARMA, INC.","OfficialName":"Albireo Pharma Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688702712.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180809"}]